

Drug Utilization Review Board Meeting

December 15, 2015

Therapeutic Class	Drug Name	Current PDL Status	DCH Decisions
Drug Reviews			
Antiinfectives, Beta-Lactams, Cephalosporins and Beta-Lactamase Inhibitors			
	Avycaz (Intravenous) Vial	NP/PA	NP/PA
	Zerbaxa (Intravenous) Vial	NP/PA	NP/PA
Gastrointestinal, Bile Acid Agents			
	Cholbam (Oral) Capsule	P/PA	P/PA
	Chenodal (Oral) Tablet	P	NP/PA
Antiinfectives, Antifungals, Invasive Aspergillosis and Mucormycosis			
	Cresemba (Oral) Capsule	NP/PA	NP/PA
	Ambisome (Intravenous) Vial	P	NP/PA
	Cancidas (Intravenous) Vial	P	NP/PA
Antineoplastic, Multiple Myeloma			
	Farydak (Oral) Capsule	P/PA	P/PA
Antihemophilic Products, Factor IX Recombinant			
	Ixinity (Intravenous) Vial	NP/PA	NP/PA
Antihemophilic Products, Factor VIII Recombinant			
	Novoeight (Intravenous) Vial	P	P
Gastrointestinal, Opioid-Induced Constipation Agents			
	Movantik (Oral) Tablet	NP/PA	NP/PA
	Relistor (Subcutaneous) Injection	P	NP/PA
Hormone Modifiers, Parathyroid Agents			
	Natpara (Subcutaneous) Cartridge	NP	NP/PA
Thrombopoietin Receptor Agonists			
	Nplate (Subcutaneous) Vial	P/PA	NP/PA

Hormone Modifiers, Acromegaly Agents			
	Signifor LAR (Intramuscular) Vial	NP/PA	NP/PA
	Somavert (Subcutaneous) Vial	P	NP/PA
Antiinfectives, Toxoplasmosis			
	Daraprim (Oral) Tablet	P	P/PA
Hematopoietics, Iron Injectables			
	Sodium Ferric Gluconate Complex (Intravenous) Vial	P	NP/PA

PDL=Preferred Drug List; P=preferred; NP=non-preferred; PA=prior authorization